about
Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccineInterethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivoTeaching empathy through poetry: a clinically based model.The effect of medical students' gender, ethnicity and attitude towards poetry-reading on the evaluation of a required, clinically-integrated poetry-based educational intervention.Ticlopidine-induced thrombotic thrombocytopenic purpura.Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.Desensitization of vascular response in vivo: contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype.Safety of low dose methotrexate in elderly patients with rheumatoid arthritisCo-occurrence of hepatocellular carcinoma and lymphoma in patients with hepatitis C virus cirrhosis.Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humansGenetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidineGenetic variation in the α1A-adrenergic receptor and phenylephrine-mediated venoconstriction.Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise.CYP2A6 genetic variation and dexmedetomidine dispositionBlacks have a greater sensitivity to α1-adrenoceptor-mediated venoconstriction compared with whites.Variation in the α(2A) adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose.Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses.Genetic variation in the alpha1B-adrenergic receptor and vascular response.Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.A polymorphism in the protein kinase C gene PRKCB is associated with α2-adrenoceptor-mediated vasoconstriction.Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine.CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.Mefloquine-induced acute hepatitis.Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.Compound cardiac toxicity of oral erythromycin and verapamil.Major bleeding caused by warfarin in a genetically susceptible patient.Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis A.Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade.Alpha2-adrenergic receptor-induced vascular constriction in blacks and whites.Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly.
P50
Q28206334-662CAD44-875D-49F4-BDF8-92D55B91F5D9Q28290776-8913D11E-9530-4A3E-A2C9-8EEC8D463F4CQ28385491-4E1E09BF-CF43-4A41-9E51-821747262F6FQ33445972-EC7F3C70-DB78-454C-8F27-829ECEF8F789Q33462930-263ABAA8-B151-4D00-B101-45D6C5039DEEQ33504648-8FB9C8CE-3489-4F28-A013-E49719206ACAQ33625202-9BE8C3A5-051E-4802-9D68-AB43DF90F174Q33646237-D80C9448-B6CA-473C-887C-CFD8841AF3E1Q33955008-62C5AB82-D648-4521-BCC7-F426B6E859C7Q34086360-B88C6743-961D-44B5-8D00-F6CF9B493754Q34199742-7AA5733B-B6A8-4CAC-A633-63BC9414718AQ34731144-598143CE-053E-4399-9369-9B0BF06523E6Q34827577-9892D009-0F22-4F11-B18C-655EBD20965EQ35642517-46A3B1C3-92D5-4285-9ED1-8FE9D704D1D1Q35658737-4EEE420B-74A4-4613-84A8-CA91A4D59576Q35830926-975B7402-5559-48F8-AD3E-B19770D25553Q35962388-096A5511-8CF7-4873-B9FA-D0E350D03433Q36769250-AF611482-9048-42AB-BFE8-28CF537D04E6Q37209353-BB70249F-50D4-48C6-8D13-48FA15D88149Q37210441-0CC7DF1C-D714-4172-934F-291744D01D10Q37351724-34B47A4A-C2CB-4C44-8D9B-B6F1959A9019Q37375138-97876F0D-49C7-4A4F-95E5-1B0A37A7F13BQ37551273-6564E3C0-A0A0-49D4-8EB1-E6402174416AQ38384338-FB388ED0-2588-4506-91A8-EC0FAD09E01FQ38719983-327FD807-FACB-4789-ACB5-6614EEF79126Q38970144-D3CE811F-0F55-4EF0-BF76-13F0307C7D67Q40174813-F67F6752-E875-4A9A-A6DB-EA65EB405F8EQ42607183-F361DDCB-5ABF-419D-8AA4-698E5993C560Q43141103-C59B4F4F-DAAF-4E2E-82FB-6764A15FBA21Q43513507-06407651-E5C0-4F68-9D7B-8A2C7E64270BQ43773276-A510A5C4-C7D1-4DEC-A8D9-3159B9583593Q43809494-7E77E0FB-7B92-4AC6-8987-F410CFF4258CQ43856655-846E7ED8-01D2-4710-A223-02503A337393Q43923513-146C1AEA-8C7E-41C0-B4C5-F2D55D4CA533Q44340794-8C5F8763-AB7D-4044-A457-6D677DE97441Q44351201-307CB0A0-2191-479F-B11C-8240D4B5616BQ44413115-95554B2D-1FEB-420F-8053-DCFA526C8DA8Q44680942-17CEE6F6-2FBD-4129-975E-53D489CE18F3Q44862814-81EF1833-6EFE-4A58-B6B4-E767E9C11A7DQ45744200-B1AFA8E1-9D97-45A9-B9A1-CA46BC6941F1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mordechai Muszkat
@ast
Mordechai Muszkat
@en
Mordechai Muszkat
@es
Mordechai Muszkat
@nl
Mordechai Muszkat
@sl
type
label
Mordechai Muszkat
@ast
Mordechai Muszkat
@en
Mordechai Muszkat
@es
Mordechai Muszkat
@nl
Mordechai Muszkat
@sl
prefLabel
Mordechai Muszkat
@ast
Mordechai Muszkat
@en
Mordechai Muszkat
@es
Mordechai Muszkat
@nl
Mordechai Muszkat
@sl
P106
P21
P31
P496
0000-0002-9520-1379
P569
2000-01-01T00:00:00Z